New projects for image interpretation and management in clinical trials totaling €1.53M for MEDIAN Technologies

Sophia Antipolis, France
  • New projects awarded* for the interpretation and management of medical images:  a phase I study for solid tumor cancers and a phase II study for prostate cancer.
  • Contract extension for a phase I/II study for solid tumor cancers.

MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, announced today that it has been selected to provide imaging solutions and services in two new clinical studies in oncology. The company has also signed an extension related to an existing contract. The total amount for MEDIAN is approximately €1.53M:

  • A  €1.06M phase I study (solid tumor cancers),
  • A €198K phase II study (prostate cancer),
  • A €268k phase I/II contract extension (solid tumor cancers).


“These new projects and contract extension are related to clinical trials sponsored by 3 major pharmaceutical companies, two of them being members of the Top 10 ”, said Jerome Windsor, VP Business Development Pharma. “All of these three pharmaceutical companies are already MEDIAN’s clients; their renewed confidence demonstrates the relevance of our added values for the management of medical images in their clinical trials”, he added.

(*) A project award is a notification announcing that the company’s solution has been chosen for a specific project. This should result in a firm contract within 18 months, subject to the confirmation of clinical results upstream.


Download Award_winning_20150303.pdf

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”


MEDIAN Technologies

Fredrik Brag
+33 4 92 90 65 82

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66